Genetics of Type 2 Diabetes Among Han Chinese
|ClinicalTrials.gov Identifier: NCT00837408|
Recruitment Status : Completed
First Posted : February 5, 2009
Last Update Posted : April 5, 2018
- To conduct a genome-wide association study (GWAS) to identify susceptibility genetic variants for diabetes among Han Chinese.
- To conduct resequencing of positional candidate gene/loci to identify likely functional variants in a subset of the cohort.
- To conduct replication studies of the top-100 scoring variants in three independent African and European ancestry samples.
- To investigate whether diabetes-associated variants discovered in European populations increase diabetes risk in Han Chinese.
- Patients 25 years of age with newly diagnosed T2D in Suizhou, China. Control subjects are nondiabetics, age and ethnically matched to patients.
- The study design for both patients and controls consists of the following steps:
- Discuss informed consent process and obtain signed informed consent form. Informed consent will be administered by trained clinic staff.
- Assign study ID (barcode)
- Administer questionnaires
- Obtain spot urine sample
- Measure blood pressure
- Obtain anthropometric measurements including body composition
- Perform finger prick for blood glucose level
- Obtain venous blood samples
- Perform eye examination
- On the following day, perform confirmatory blood glucose for the small subset of participants requiring confirmation of previous test result
- DNA extraction of stored samples will be done at either the National Institutes of Health or the laboratory in China.
- GWAS will be conducted using publicly available software packages.
|Condition or disease|
|Diabetes Obesity Hypertension Retinopathy Nephropathy|
|Study Type :||Observational|
|Actual Enrollment :||2379 participants|
|Official Title:||Genetics of Type 2 Diabetes Among Han Chinese|
|Study Start Date :||February 3, 2009|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00837408
|Suizhou Central Hospital|
|Hu Bei, China|
|Principal Investigator:||Charles N Rotimi, M.D.||National Human Genome Research Institute (NHGRI)|